Oral submucous fibrosis--treatment with hyalase. 1985

P K Kakar, and R K Puri, and V P Venkatachalam

Oral Submucous Fibrosis (OSMF) is a disease of unknown etiology. A total of 96 patients with Oral Submucous Fibrosis have received four regimens of treatment--local dexamethasone, local hyaluronidase, local combination of dexamethasone and hyaluronidase, and local placental extract. The patients were followed up for a period varying from 3 months to 2 years. The group of patients receiving hyaluronidase alone showed quicker improvement in symptoms although its combination with dexamethasone gave somewhat better longer-term results. A new regimen for the treatment of submucous fibrosis is recommended.

UI MeSH Term Description Entries
D009059 Mouth Diseases Diseases involving the MOUTH. Disease, Mouth,Diseases, Mouth,Mouth Disease
D009914 Oral Submucous Fibrosis Irreversible FIBROSIS of the submucosal tissue of the MOUTH. Fibroses, Oral Submucous,Fibrosis, Oral Submucous,Oral Submucous Fibroses,Submucous Fibroses, Oral,Submucous Fibrosis, Oral
D010924 Placental Extracts Extracts prepared from placental tissue; they may contain specific but uncharacterized factors or proteins with specific activities. Placental Extract,Extract, Placental,Extracts, Placental
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006821 Hyaluronoglucosaminidase An enzyme that catalyzes the random hydrolysis of 1,4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. (From Enzyme Nomenclature, 1992) There has been use as ANTINEOPLASTIC AGENTS to limit NEOPLASM METASTASIS. Hyaluronidase,Duran-Reynals Permeability Factor,GL Enzyme,Hyaglosidase,Hyaluronate Hydrolase,Wydase,Duran Reynals Permeability Factor,Factor, Duran-Reynals Permeability,Hydrolase, Hyaluronate,Permeability Factor, Duran-Reynals
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

P K Kakar, and R K Puri, and V P Venkatachalam
March 2016, Journal of maxillofacial and oral surgery,
P K Kakar, and R K Puri, and V P Venkatachalam
January 2010, Evidence-based dentistry,
P K Kakar, and R K Puri, and V P Venkatachalam
October 1981, International journal of oral surgery,
P K Kakar, and R K Puri, and V P Venkatachalam
January 1971, Diastema,
P K Kakar, and R K Puri, and V P Venkatachalam
January 1994, The National medical journal of India,
P K Kakar, and R K Puri, and V P Venkatachalam
April 1995, BMJ (Clinical research ed.),
P K Kakar, and R K Puri, and V P Venkatachalam
October 1987, International journal of oral and maxillofacial surgery,
P K Kakar, and R K Puri, and V P Venkatachalam
November 1971, Journal of the Indian Medical Association,
P K Kakar, and R K Puri, and V P Venkatachalam
January 1993, The National medical journal of India,
P K Kakar, and R K Puri, and V P Venkatachalam
October 1967, The Dental journal of Malaysia & Singapore,
Copied contents to your clipboard!